Equities Analysts Issue Forecasts for BNTC Q2 Earnings

Benitec Biopharma Inc. (NASDAQ:BNTC) – Analysts at HC Wainwright issued their Q2 2025 earnings estimates for Benitec Biopharma in a note issued to investors on Monday, December 16th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will post earnings of ($0.27) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($4.33) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

Other analysts have also issued reports about the stock. Oppenheimer began coverage on shares of Benitec Biopharma in a research note on Wednesday, October 16th. They set an “outperform” rating and a $35.00 target price on the stock. Baird R W upgraded shares of Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a report on Friday, October 18th. Robert W. Baird assumed coverage on Benitec Biopharma in a report on Friday, December 13th. They set an “outperform” rating and a $30.00 price target for the company. Finally, JMP Securities increased their price objective on Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a report on Monday, October 14th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Benitec Biopharma presently has an average rating of “Buy” and a consensus price target of $24.43.

Benitec Biopharma Price Performance

BNTC opened at $12.17 on Thursday. The stock has a market capitalization of $282.54 million, a price-to-earnings ratio of -4.29 and a beta of 0.88. The business has a fifty day moving average price of $10.77 and a 200 day moving average price of $9.40. Benitec Biopharma has a 12 month low of $2.69 and a 12 month high of $13.29.

Insider Buying and Selling at Benitec Biopharma

In related news, Director Suvretta Capital Management, L bought 42,000 shares of the stock in a transaction on Tuesday, December 3rd. The shares were bought at an average cost of $9.60 per share, for a total transaction of $403,200.00. Following the purchase, the director now owns 7,957,365 shares of the company’s stock, valued at $76,390,704. This trade represents a 0.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Benitec Biopharma

Large investors have recently modified their holdings of the business. GAMMA Investing LLC increased its stake in Benitec Biopharma by 20.3% in the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 1,102 shares in the last quarter. Acuta Capital Partners LLC acquired a new stake in Benitec Biopharma in the third quarter valued at $274,000. Simplify Asset Management Inc. purchased a new position in shares of Benitec Biopharma in the second quarter valued at $358,000. Geode Capital Management LLC raised its stake in shares of Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock worth $772,000 after buying an additional 20,012 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in shares of Benitec Biopharma during the 2nd quarter worth $5,881,000. 52.19% of the stock is owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.